What is Zeo ScientifiX Price-to-Operating-Cash-Flow?
As of today (2024-05-13), Zeo ScientifiX's share price is $1.10.
Zeo ScientifiX's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jan. 2024 was $176.27. Hence, Zeo ScientifiX's Price-to-Operating-Cash-Flow Ratio for today is 0.01.
The historical rank and industry rank for Zeo ScientifiX's Price-to-Operating-Cash-Flow or its related term are showing as below:
ZEOX'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0.01 Med: 0.01 Max: 0.02
Current: 0.01
During the past 13 years, Zeo ScientifiX's highest Price-to-Operating-Cash-Flow Ratio was 0.02. The lowest was 0.01. And the median was 0.01.
Zeo ScientifiX's Cash Flow from Operations per share for the
three
months ended in Jan. 2024 was $0.00.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jan. 2024 was $176.27.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -388.00% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -251.00% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was -74.50% per year.
During the past 13 years, Zeo ScientifiX's highest 3-Year average Operating Cash Flow per Share Growth Rate was 39.50% per year. The lowest was -676.00% per year. And the median was -89.35% per year.
Zeo ScientifiX Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Zeo ScientifiX's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zeo ScientifiX Price-to-Operating-Cash-Flow Chart
|
Zeo ScientifiX Annual Data
|
|
Trend |
Oct14 |
Oct15 |
Oct16 |
Oct17 |
Oct18 |
Oct19 |
Oct20 |
Oct21 |
Oct22 |
Oct23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
Zeo ScientifiX Quarterly Data
|
|
Apr19 |
Jul19 |
Oct19 |
Jan20 |
Apr20 |
Jul20 |
Oct20 |
Jan21 |
Apr21 |
Jul21 |
Oct21 |
Jan22 |
Apr22 |
Jul22 |
Oct22 |
Jan23 |
Apr23 |
Jul23 |
Oct23 |
Jan24 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
0.01 |
0.02 |
- |
0.01 |
Competitive Comparison of Zeo ScientifiX's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Zeo ScientifiX's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zeo ScientifiX's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Zeo ScientifiX's Price-to-Operating-Cash-Flow falls into.
Zeo ScientifiX Price-to-Operating-Cash-Flow Calculation
Zeo ScientifiX's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 1.10 | / | 176.272 |
| = | 0.01 |
Zeo ScientifiX's Share Price of today is $1.10.
Zeo ScientifiX's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $176.27.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Zeo ScientifiX (Zeo ScientifiX) Business Description
Traded in Other Exchanges
N/A
Address
3321 College Avenue, Suite 246, Davie, FL, USA, 33314
Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.
Executives
| Skycrest Holdings, Llc |
10 percent owner |
1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020 |
| Harry L. Leider |
director, officer: CEO and Director |
C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116 |
| Howard Lawrence Golub |
officer: Executive Vice President & CSO |
23648 SEPTEMBER SUN SQ, ASHBURN VA 20148 |
| Matthew Phillip Sinnreich |
officer: COO and Acting CEO |
4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139 |
| Steven Jerry Glauser |
director |
1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131 |
| Leathem S Stearn |
director |
2306 BAY DRIVE, POMPANO BEACH FL 33062 |
| Charles Luther Bretz |
director |
58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432 |
| Bhupendra Kumar Modi |
director |
6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985 |
| Gurvinder Pal Singh |
director |
E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048 |
| John F Chiste |
director |
|
| Ryan C Likes |
officer: Chief Operating Officer |
1116 MEADOWBROOK AVE., LOS ANGELES CA 90019 |
| Greyt Ventures, Llc |
10 percent owner |
GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180 |
| Wendy Grey |
10 percent owner |
GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180 |
| Ian T Bothwell |
10 percent owner, officer: Chief Financial Officer |
77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211 |
| Albert Mitrani |
director, officer: Chief Executive Officer |
4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140 |
Zeo ScientifiX (Zeo ScientifiX) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZEOX has been successfully added to your